As an alternative, the tumor mutation burden (TMB), the number of mutations present in the tumor per coding area, has been suggested as a better biomarker for predicting anti-PD-(L)1 therapy outcomes across many cancers, including NSCLC [13,14]. Here, CD274 is linked to non-small cell lung carcinoma.